Inventor · disambiguated record
Jason C. Rech
Also filed as: RECH JASON · RECH JASON C · RECH JASON CHRISTOPHER
21 granted patents·7 pending applications·133 citations·filing 2008–2023
94Inventor score
Files withJANSSEN PHARMACEUTICA NV16UNIV MICHIGAN REGENTS6BRANSTETTER BRYAN JAMES2Jansssen Pharmaceutica NV2BERTHELOT DIDIER JEAN-CALUDE1
Top patents by PatentIndex Score
28 records- 0194US10071988B2Substituted 1,2,3-triazoles as NR2B-selective NMDA modulatorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Sep 11, 2018·17 cites·22 claims
- 0294US9963447B2Substituted 4-azaindoles and their use as GluN2B receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted May 8, 2018·17 cites·26 claims
- 0393US10617676B2Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Apr 14, 2020·12 cites·27 claims
- 0493US10233173B2Substituted 1,2,3-triazoles as NR2B-selective NMDA modulatorsJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Mar 19, 2019·13 cites·20 claims
- 0592US10377753B2Substituted 4-azaindoles and their use as GluN2B receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Aug 13, 2019·13 cites·31 claims
- 0691US10112937B2P2X7 modulators and methods of useJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Oct 30, 2018·11 cites·40 claims
- 0789US11207298B2Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Dec 28, 2021·2 cites·32 claims
- 0885US10766880B2Substituted 1,2,3-triazoles as NR2B-selective NMDA modulatorsJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Sep 8, 2020·2 cites·27 claims
- 0985US9040534B2[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulatorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted May 26, 2015·6 cites·20 claims
- 1085US8431704B2Quinoline or isoquinoline substituted P2X7 antagonistsLOVE CHRISTOPHER JOHN·Filed 2009·Granted Apr 30, 2013·24 cites·12 claims
- 1184US10150766B2P2X7 modulatorsJansssen Pharmaceutica NV·Filed 2015·Granted Dec 11, 2018·7 cites·36 claims
- 1281US2023338341A1SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORSJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 1377US8288397B2Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1BRANSTETTER BRYAN JAMES·Filed 2008·Granted Oct 16, 2012·2 cites·20 claims
- 1475US11759455B2Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulatorsJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Sep 19, 2023·0 cites·25 claims
- 1575US8614201B2Heterocyclic amides as modulators of TRPA1BERTHELOT DIDIER JEAN-CALUDE·Filed 2010·Granted Dec 24, 2013·6 cites·17 claims
- 1671US8637527B2Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1BRANSTETTER BRYAN JAMES·Filed 2012·Granted Jan 28, 2014·1 cites·19 claims
- 1767US12338243B2P2X7 modulatorsJANSSEN PHARMACEUTICA NV·Filed 2022·Granted Jun 24, 2025·0 cites·23 claims
- 1865US11999731B2EGFR dimer disruptors and use of the sameUNIV MICHIGAN REGENTS·Filed 2022·Granted Jun 4, 2024·0 cites·20 claims
- 1961US10053463B2Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulatorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Aug 21, 2018·0 cites·33 claims
- 2060US9440978B2Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1JANSSEN PHARMACEUTICA NV·Filed 2013·Granted Sep 13, 2016·0 cites·19 claims
- 2156US11358965B2EGFR dimer disruptors and use of the sameUNIV MICHIGAN REGENTS·Filed 2019·Granted Jun 14, 2022·0 cites·19 claims
- 2255US2016376291A1Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1JANSSEN PHARMACEUTICA NV·Filed 2016·Application pending·0 cites
- 2354US2024018144A1Synthesis of EGFR ModulatorsUNIV MICHIGAN REGENTS·Filed 2021·Application pending·0 cites
- 2452US2023374017A1Compositions and methods for activating pyruvate kinaseUNIV MICHIGAN REGENTS·Filed 2021·Application pending·0 cites
- 2551US10047092B2Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulatorsJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Aug 14, 2018·0 cites·11 claims
- 2649US2023097789A1Inhibitors of egfr, kras, braf, and other targets and use of the sameUNIV MICHIGAN REGENTS·Filed 2021·Application pending·0 cites
- 2748US2023098205A1Inhibitors of egfr, kras, braf, and other targets and use of the sameUNIV MICHIGAN REGENTS·Filed 2021·Application pending·0 cites
- 2839US2018118749A1P2x7 modulatorsJansssen Pharmaceutica NV·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →